ExPLoRNA specializes in novel cap analogs, the starting part of mRNA that is crucial for enabling successful production of the encoded protein: with its tech increasing protein production.
A 14-month project, which aims to better understand the benefits of the tech in terms of reducing the RNA dosage needed for vaccination and monoclonal antibody production, will be funded by the $813,578 grant from the Bill & Melinda Gates Foundation.
The planned experiments include the use of the state-of-the-art, clinically validated lipid nanoparticle (LNP) formulations from Vancouver-based Acuitas Therapeutics (which already provides LNP technology for mRNA-based COVID-19 vaccines).
ExPLoRNA Therapeutics is the first Polish biotech company to receive funding from Bill & Melinda Gates Foundation.
